Lipid goal attainment in post‐acute coronary syndrome patients in China: Results from the 6‐month real‐world dyslipidemia international study II. Issue 11 (15th October 2021)

• Record Type: Journal Article
• Authors: Gong, Yanjun; Li, Xuan; Ma, Xiang; Yu, Hongwei; Li, Ying; Chen, Jiyan; Zhang, Guochun; Wang, Bin; Qi, Xiaoyong; Meng, Haiyan; Wang, Xiaofeng; Mu, Jianjun; Hu, Xitian; Wang, Jingping; Liu, Shaowen; Liu, Gang; Yang, Zhenyu; Zhou, Yujie; Kong, Xiangqing; Yan, Yuhu; Wang, Changqian; Wang, Jian' An; Wang, Lijun; Fu, Guosheng; Wei, Lin; Peng, Daoquan; Zhang, Shuyang; Li, Ruogu; Mao, Anhua; Bian, Rui; Tang, Wenmin; Ran, Yuqin; Jiang, Jie; Huo, Yong;
• Is Part Of: Clinical cardiology. Volume 44:Issue 11(2021)
• Page Start: 1575
• Page End: 1585
• Publication Date: 2021-10-15
• Subjects: acute coronary syndrome -- DYSIS II -- LDL‐C goal -- lipid‐lowering therapy -- statin; Cardiology -- Periodicals; 616.12005
• DOI: 10.1002/clc.23725
• Languages: English
• ISSNs: 0160-9289

Abstract

Abstract: Background: Dyslipidemia International Study II (DYSIS II)‐China was conducted to determine the low‐density lipoprotein cholesterol (LDL‐C) goal (<1.8 mmol/L) attainment rate in patients with post‐acute coronary syndrome (ACS). Hypothesis: Compliance with treatment guideline recommendations improves the LDL‐C goal attainment rate in post‐ACS patients. Methods: This multicenter prospective observational study conducted at 28 tertiary hospitals determined the LDL‐C goal attainment rates at admission and 6‐month follow‐up in patients on lipid‐lowering treatment (LLT) for ≥3 months and those not on LLT (LLT‐naive or off LLT for ≥3 months) at admission. Predictors of goal attainment at 6 months were identified using multivariate logistic regression. Results: The LDL‐C goal attainment rate at admission in 1102/1103 enrolled patients was 17.1%; it was 41.2% among 752 patients with available lipid results at 6 months. The distance to goal was 0.7 mmol/L at 6 months. Statin monotherapy was the most prescribed LLT. Only 7.7% of patients were receiving statin + ezetimibe and 8.4% of patients were receiving an atorvastatin‐equivalent dose of ≥40 mg/day at 6 months. Being male (odds ratio [OR] 1.7, 95% confidence interval [CI] 1.1–2.6) and undergoing percutaneous coronary intervention during index hospitalization (OR 1.5, 95% CI 1.1 to 2.1) were the independent predictors for LDL‐C goal attainment. Conclusions: This real‐world DYSIS II study in China reports a low LDL‐C goal attainment rate in post‐ACS patients even after 6 months of LLT. Lack of intensification of statin therapy and underutilization of combinations suggest gaps between real‐world treatment practices and guideline recommendations.